NUK - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources NUK. For full access, REGISTER.

1 2 3 4 5
hits: 440
1.
  • Advances in Risk Classification and Treatment Strategies for Neuroblastoma
    Pinto, Navin R; Applebaum, Mark A; Volchenboum, Samuel L ... Journal of clinical oncology, 09/2015, Volume: 33, Issue: 27
    Journal Article
    Peer reviewed
    Open access

    Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and cooperative groups were disparate, limiting the ...
Full text

PDF
2.
  • Revised Neuroblastoma Risk ... Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
    Irwin, Meredith S; Naranjo, Arlene; Zhang, Fan F ... Journal of clinical oncology, 10/2021, Volume: 39, Issue: 29
    Journal Article
    Peer reviewed
    Open access

    Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by ...
Full text
3.
  • Carboplatin and Paclitaxel ... Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
    Miller, David S; Filiaci, Virginia L; Mannel, Robert S ... Journal of clinical oncology, 11/2020, Volume: 38, Issue: 33
    Journal Article
    Peer reviewed
    Open access

    Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied ...
Full text

PDF
4.
  • Neuroblastoma Neuroblastoma
    Maris, John M, MD; Hogarty, Michael D, MD; Bagatell, Rochelle, MD ... The Lancet (British edition), 06/2007, Volume: 369, Issue: 9579
    Journal Article
    Peer reviewed

    Summary The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of cure varying widely according to age at diagnosis, extent of disease, and tumour biology. A subset of tumours ...
Full text
5.
  • Purged versus non-purged pe... Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
    Kreissman, Susan G, Prof Dr; Seeger, Robert C, Prof; Matthay, Katherine K, Prof ... The lancet oncology, 09/2013, Volume: 14, Issue: 10
    Journal Article
    Peer reviewed
    Open access

    Summary Background Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. ...
Full text

PDF
6.
  • Children's Oncology Group's... Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
    Park, Julie R.; Bagatell, Rochelle; London, Wendy B. ... Pediatric blood & cancer, June 2013, Volume: 60, Issue: 6
    Journal Article
    Peer reviewed

    Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy ...
Full text
7.
  • Modulation of matrix remode... Modulation of matrix remodeling by SPARC in neoplastic progression
    Chlenski, Alexandre; Cohn, Susan L. Seminars in cell & developmental biology, 02/2010, Volume: 21, Issue: 1
    Journal Article
    Peer reviewed

    SPARC is a matricellular glycoprotein that mediates interactions between cells and their microenvironment. It is produced at sites of tissue remodeling, where it regulates matrix deposition and ...
Full text
8.
  • Predicting tumor cell line ... Predicting tumor cell line response to drug pairs with deep learning
    Xia, Fangfang; Shukla, Maulik; Brettin, Thomas ... BMC bioinformatics, 12/2018, Volume: 19, Issue: Suppl 18
    Journal Article
    Peer reviewed
    Open access

    The National Cancer Institute drug pair screening effort against 60 well-characterized human tumor cell lines (NCI-60) presents an unprecedented resource for modeling combinational drug activity. We ...
Full text

PDF
9.
  • TET1-Mediated Hydroxymethyl... TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma
    Mariani, Christopher J.; Vasanthakumar, Aparna; Madzo, Jozef ... Cell reports (Cambridge), 06/2014, Volume: 7, Issue: 5
    Journal Article
    Peer reviewed
    Open access

    The ten-eleven-translocation 5-methylcytosine dioxygenase (TET) family of enzymes catalyzes the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), a modified cytosine base that ...
Full text

PDF
10.
  • Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project
    Brisse, Hervé J; McCarville, M Beth; Granata, Claudio ... Radiology, 10/2011, Volume: 261, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy. ...
Full text

PDF
1 2 3 4 5
hits: 440

Load filters